SENSEI BIOTHERAPEUTICS INC (SNSE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$13.85+6.54%
Close 2026-06-15 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SNSE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
SNSE — M&A activity — Termination of a Material Definitive Agreement
Dated 2026-06-15
Termination of a Material Definitive Agreement. As previously disclosed, on March 15, 2022, Faeth Therapeutics, Inc., formerly known as Sensei Biotherapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Prior Sales Agreement”) with Jefferies LLC (“Jefferies”), pursuant to which the Company from time to time may offer and sell shares of its common stock through or to the Agent having an aggregate offering price of up to $50 million. On June 10, 2026, the Company delivered writte…
Why it matters: Good data could show PIKTOR's potential. This may attract more investors.
Supportive ifTopline data from the Phase 2 trial in advanced endometrial cancer is due in late 2026.
Worry ifData from the trial is disappointing or delayed beyond expectations.
Why it matters: Good data could increase trust in the company's plans and future growth.
Supportive ifA press release announcing positive results from the Phase 2 trial.
Worry ifThe trial results are negative or inconclusive.
Why it matters: Interim data will show how PIKTOR is performing. This will affect future strategies.
Watch forInterim data from the Phase 1b/2 trial expected in 2027.
Also watch forIf no interim data is released by 2027, it may mean problems in the trial.
Why it matters: Bigger losses would show worse financial health. It would also mean cash burn problems.
Worry ifOperating losses were over $10M for Q2 2026.
Less concerning ifOperating losses were under $10M for Q2 2026.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$320 on $10,000 · ±3.2% | How much price usually moves either way. |
| Bad day | $1,152 loss on $10,000 · 11.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,923 loss on $10,000 · 69.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Interim data will show how well PIKTOR treats advanced breast cancer. This will affect future trials.
Watch forInterim data from the Phase 1b/2 trial shows positive results for PIKTOR in advanced breast cancer.
Also watch forInterim data from the Phase 1b/2 trial shows negative results for PIKTOR in advanced breast cancer.
Why it matters: This data will show if PIKTOR is effective. Positive results could boost investor confidence.
Supportive ifThe Phase 2 trial data for PIKTOR in advanced endometrial cancer is out.
Worry ifData shows PIKTOR is ineffective or does not meet primary endpoints.
Why it matters: High cash burn can affect future operations. Good management is key for survival.
Worry ifManagement reports a big drop in cash burn or operating losses.
Less concerning ifOperating losses increase or cash burn remains high without a clear plan.
Why it matters: Approval will lead to a significant increase in common shares. This could affect share price and market perception.
Watch forStockholders approve the change of Series B preferred stock.
Also watch forStockholders did not approve the change. This stops the change from happening.